Dr. Lal PathLabs becomes south Asia’s first diagnostic chain to offer advance test for amyloidosis: a rare, life-threatening protein disorder

Medical testing laboratory Dr. Lal PathLabs said on Tuesday that it has become south Asia’s first diagnostic chain to offer an advance test for amyloidosis, a rare but critical disease caused by caused by clumps of misfolded proteins accumulating in organs and tissues.

Amyloidosis is a serious condition as the protein buildup often affects multiple organs and is progressive, leading to organ dysfunction and potentially life-threatening organ failure. Through this test, doctors will be able to determine the specific type of Amyloid—the clumps of misfolded proteins—enabling targeted treatment and better outcomes. Currently, more than 40 types of proteins have been discovered.

The breakthrough test—called Amyloid Typing by Laser Capture Microdissection and Mass Spectrometry—has been launched under the guidance of National Amyloidosis Centre in the United Kingdom. Samples can be collected from anywhere in India and sent to Dr. Lal PathLabs’ National Reference Lab in New Delhi for testing.

“Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection and Mass Spectrometry, allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care,” said Dr. Alok Sharma, R&D head and director, Renal Pathology and Electron Microscopy.